CITIUS PHARMACEUTICALS INC's ticker is CTXR and the CUSIP is 17322U207. A total of 74 filers reported holding CITIUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,220 | -43.0% | 50,000 | 0.0% | 0.01% | -44.4% |
| Q2 2023 | $60,000 | +2.6% | 50,000 | 0.0% | 0.01% | -10.0% |
| Q1 2023 | $58,500 | +48.1% | 50,000 | 0.0% | 0.01% | +42.9% |
| Q4 2022 | $39,500 | -35.2% | 50,000 | 0.0% | 0.01% | -46.2% |
| Q3 2022 | $61,000 | +32.6% | 50,000 | 0.0% | 0.01% | +44.4% |
| Q2 2022 | $46,000 | -48.9% | 50,000 | 0.0% | 0.01% | -35.7% |
| Q1 2022 | $90,000 | +16.9% | 50,000 | 0.0% | 0.01% | +27.3% |
| Q4 2021 | $77,000 | -24.5% | 50,000 | 0.0% | 0.01% | -38.9% |
| Q3 2021 | $102,000 | -41.4% | 50,000 | 0.0% | 0.02% | -40.0% |
| Q2 2021 | $174,000 | +95.5% | 50,000 | 0.0% | 0.03% | +87.5% |
| Q1 2021 | $89,000 | +74.5% | 50,000 | 0.0% | 0.02% | +60.0% |
| Q4 2020 | $51,000 | +96.2% | 50,000 | +100.0% | 0.01% | +66.7% |
| Q3 2020 | $26,000 | +73.3% | 25,000 | +25.0% | 0.01% | +100.0% |
| Q3 2019 | $15,000 | -77.9% | 20,000 | -50.0% | 0.00% | -85.7% |
| Q3 2018 | $68,000 | -26.1% | 40,000 | 0.0% | 0.02% | -25.0% |
| Q2 2018 | $92,000 | – | 40,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Inspire Advisors, LLC | 196,867 | $181,000 | 0.05% |
| Wealth Advisory Solutions, LLC | 156,850 | $144,000 | 0.04% |
| Horst & Graben Wealth Management LLC | 75,722 | $70,000 | 0.02% |
| Ergoteles LLC | 451,890 | $416,000 | 0.01% |
| Miller Investment Management, LP | 50,000 | $46,000 | 0.01% |
| Virtu Financial LLC | 81,410 | $75,000 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 17,342 | $16,000 | 0.00% |
| Kestra Advisory Services, LLC | 71,102 | $65,000 | 0.00% |
| Csenge Advisory Group | 15,000 | $14,000 | 0.00% |
| Qube Research & Technologies Ltd | 121,281 | $112,000 | 0.00% |